Introduction
Use this section to understand and follow national and Idaho guidelines to determine whom to treat for latent tuberculosis infection (LTBI); select appropriate treatment regimens and dosages; monitor patients for adverse reactions; monitor patients' adherence to treatment; determine whether and when therapy is completed; provide treatment in special situations, such as when a patient is pregnant or has tuberculosis (TB)-human immunodeficiency virus (HIV) coinfection.
Prevention of TB has major public health implications, so it is essential to identify and treat all those with risk factors for TB disease. 1 LTBI is the presence of Mycobacterium tuberculosis organisms (tubercle bacilli), with no symptoms and no radiographic or bacteriologic evidence of TB disease. 2 A person with LTBI is noninfectious but can develop active TB disease. Persons with increased risk for developing TB include those who have had recent infection with M. tuberculosis and those who have clinical conditions associated with an increased risk for the progression of LTBI to TB disease.
To control and prevent TB, our healthcare resources and efforts in Idaho should be directed to meet the priorities outlined in the 2005 "Controlling Tuberculosis in the United States: Recommendations from the American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America." One of the recommended strategies to achieve the goal of reduction of TB morbidity and mortality is the identification and treatment of persons with LTBI at risk for progression to TB. 3 Targeted tuberculin testing for LTBI is a strategic component of TB control that identifies persons at high risk for developing TB who would benefit by treatment of LTBI, if detected. Persons with increased risk for developing TB include those who have had recent infection with M. tuberculosis and those who have clinical conditions that are associated with an increased risk for progress of LTBI to active TB.
Healthcare providers must communicate the risks and benefits of treatment to their patients and encourage adherence and treatment completion. Treatment of LTBI is essential to controlling and eliminating TB in the U.S. LTBI treatment substantially reduces the risk that TB infection will progress to disease. 4 Depending upon adherence and length of treatment, completing treatment for LTBI can reduce the risk of TB disease by 65-90%.
5

I D A H O T U B E R C U L O S I S P R O G R A M M A N U A L
Treatment of LTBI 8. 4 
Whom to Treat
Determine whom to treat for latent tuberculosis infection (LTBI). Certain groups are at high risk of developing tuberculosis (TB) disease once infected, so make every effort to begin appropriate treatment and to ensure those persons complete the entire course of treatment for LTBI. 
Susceptible and Vulnerable Contacts
A contact is someone who has been exposed to M. tuberculosis infection by sharing air space with a person with infectious TB. 8 Susceptible contacts are those who are more likely to become ill with TB disease if they are infected, and vulnerable contacts are those who could suffer severe morbidity if they had TB disease. 9 Persons who are susceptible and/or vulnerable to TB disease are candidates for window period treatment, which is treatment for presumptive TB infection during the interval between infection and detectable skin test reactivity. The National Tuberculosis Controllers Association (NTCA) and the Centers for Disease Control and Prevention (CDC) recommend that the window period be estimated at eight to 10 weeks. 10 The following contacts with initially negative TST results should receive treatment for LTBI after TB disease has been ruled out by clinical examination and chest radiograph:
1. contacts younger that 5 years of age (with highest priority given to those under 3 years)
contacts with HIV infection or who are otherwise immunocompromised
If the second skin test result is negative and the contact is immunocompetent (including immunocompetent young children) and no longer exposed to infectious TB, treatment for LTBI may be discontinued, and further follow-up is unnecessary. Tuberculin Skin Test Results 
Treatment Regimens and Dosages
Select appropriate treatment durations, regimens, and dosages. Treatment of latent tuberculosis infection (LTBI) is an essential part of the strategy to eliminate tuberculosis (TB) in the U.S. Persons with LTBI who are considered at increased risk for TB should be offered treatment. 13 There are several treatment regimens available for the treatment of LTBI, and providers should discuss options with patients. Persons who are at especially high risk for TB, and either are suspected of nonadherence or are on an intermittent dosing regimen, should be considered for directly observed therapy (DOT). This method of treatment is especially appropriate when a household member is on DOT for TB disease or in institutions and facilities where a staff member can observe treatment.
For a list of high-risk persons, see the "Whom to Treat" topic in this section.
High-risk contacts (under 5 years of age or immunocompromised) should be started promptly on treatment for LTBI. For more information on time frames, see the "Time Frames for Contact Investigation" topic in the Contact Investigation section.
Regimens
Identify an appropriate regimen for the patient using the national guidelines provided in Table 1 below. This duration of therapy is not indicated for HIV-infected persons, those with fibrotic lesions on chest radiographs, or children.
B (I) C (I) INH
Twice weekly for 6 months § DOT must be used with twice-weekly dosing.
B (II) C (I)
RIF
Daily for 4 months in adults
Daily for 6 months in children RIF is used for persons who are contacts of patients with INH-resistant, RIF-susceptible TB. Some anti-retroviral drugs, such as the protease inhibitors and NNRTIs, have interactions with the rifamycins. Clinicians should consult Web-based updates or experts for the latest specific recommendations. The optimal length of RIF therapy in children with LTBI is not known; however, the American Academy of Pediatrics recommends 6 months of treatment. 
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The regimen of rifampin (RIF) and pyrazinamide (PZA) for two months is no longer recommended for treatment of LTBI because of its association with severe liver injury. 
Dosages
Once the appropriate regimen has been identified, refer to Table 2 for instructions on dosages for each drug. The information in Table 2 is taken from national American Thoracic Society (ATS) and CDC guidelines. For information on information on ordering drugs, see the Supplies, Materials, and Services section. 
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Side Effects and Adverse Reactions
The patient should be monitored by a registered nurse and/or clinician or case manager monthly for signs and symptoms of adverse reactions until treatment is completed. If a patient is symptomatic, the provider should be consulted and the patient monitored more frequently. Chemistries and complete blood count (CBC), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), or other tests based on specific drugs should be done periodically. See As is true with all medications, combination chemotherapy for tuberculosis is associated with a predictable incidence of adverse effects, some mild, some serious. 19 Adverse effects are fairly common and often manageable. Although it is important to be attuned to the potential for adverse effects it is at least equally important that first-line drugs not be stopped without adequate justification. 20 However, adverse reactions can be severe, and thus, it is important to recognize adverse reactions that indicate when a drug should not be used. Mild adverse effects can generally be managed with symptomatic therapy; whereas with more severe effects, the offending drug or drugs must be discontinued. 21 In addition, proper management of more serious adverse reactions often requires expert consultation. 22 Monitor patients for side effects and adverse reactions following the basic monitoring steps listed below.
Basic Monitoring Steps 
2.
While on treatment, all patients should be evaluated in person, at baseline (before starting treatment), and then monthly for side effects and adverse reactions.
3.
The common side effects of and adverse reactions to drugs used to treat for latent TB infection (LTBI) are listed in 
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Reporting Reactions
The table below is intended for use by a healthcare worker who performs case management services. The healthcare worker should instruct the patient to report to the provider the side effects and adverse reactions listed in Table 3 .
If a patient reports to a healthcare worker a potentially serious adverse reaction, the healthcare worker should call the patient's provider immediately and alert the Idaho State TB program by calling (208) 334-5939.
If a patient reports to a healthcare worker a potentially less severe side effect, the healthcare worker should call the patient's provider immediately and monitor the patient. 
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Checking for Side Effects or Adverse Reactions by Antituberculosis Drug
Refer to 
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Adherence
Monitor patients for adherence to self-administered latent tuberculosis infection (LTBI) treatment regimens monthly throughout treatment. 27 It is difficult to identify who will and who will not be adherent. 28 If patients do not take medicine as directed, the effectiveness of the regimen decreases, and the patient will be at greater risk of progressing to disease in the future and of infecting others.
Monthly Assessment of Adherence
At each visit, the clinician should assess adherence by doing the following:
1. Ask patients how many doses they have missed since their last refill. If patients are asked, "Did you take all your pills last month?" the natural inclination is to agree and say "yes" even if they did not.
2.
Have patients bring their bottle of medicine to the refill appointment and count how many pills are left.
3.
If adherence problems are identified, include patients in the problem solving process.
a. Ask patients why they think that doses are missed and what could be done better: change the time of day, the location where they keep or take their pills, etc.
b. Find out if there are barriers to obtaining refills in a timely manner that could be corrected.
c.
Review with patients what they believe is their risk of developing tuberculosis (TB) if medicine is not taken. Provide education again as needed.
d. Mutually agree on a plan to improve adherence.
e. Praise patients for cooperation.
4.
If adherence seems to be good, praise patients.
For information on what to include in a patient education session, see the Patient Education section.
Directly Observed Therapy
Patients in high-risk groups are strongly recommended for directly observed therapy (DOT).
• Young children who are recent contacts to infectious cases 
Completion of Therapy
Determine whether and when therapy is completed based on the total number of doses administered, not on the duration of therapy. When patients have had lapses in therapy but are still able to complete the recommended number of doses in the allotted time period, encourage them to complete therapy.
Assess patients who will not complete appropriate therapy within the time frame specified to determine whether or not to restart treatment. If the decision is made to retreat the patient, then restart the entire regimen and follow recommended treatment plan of therapy. Specific factors to consider when determining whether to restart treatment include the following:
Individual's risk for developing tuberculosis (TB) disease
Total number of doses of latent tuberculosis infection (LTBI) treatment administered
Time elapsed since the last dose of treatment for LTBI Patient adherence issues (previous attempts at completion, willingness to continue, etc.)
Give nonadherent patients at very high risk of developing TB disease every opportunity to complete treatment for LTBI. Consider these patients for intermittent therapy with directly observed therapy, and evaluate the use of incentives and enablers. 29 Treatment of LTBI in contacts is considered a priority in TB control activities. Make every effort to assure completion of treatment in contacts.
All contacts who are being treated for infection should be seen face-to-face by a healthcare provider monthly. Incentives and enablers are recommended as aids to adherence, and the healthcare provider should educate the patient about TB, its treatment, and the signs of adverse drug effects at each patient encounter.
30
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Treatment of LTBI 8.20 Table 5 describes the duration of therapy and the number of doses that patients are required to take to complete therapy and the time frame within which the total number of doses must be administered for completion of therapy. Make every effort to encourage patients to adhere to the LTBI treatment regimen. However, if a patient has failed three attempts to complete treatment, no further effort may be merited. The healthcare provider should contact patients who interrupt therapy and are at high risk of developing TB disease (for example, contacts of patients with infectious TB, Human immunodeficiency virus (HIV)-infected patients, or TB Class 4 patients) for reevaluation. 32 For consultation regarding completion of therapy and considerations to examine when restarting treatment in noncompliant patients, contact the Idaho State TB Program at (208) 334-5939.
Alcoholism
Because of the effectiveness of isoniazid (INH) and rifampin (RIF), they should be used if at all possible, even in the presence of preexisting liver disease. Drug-induced hepatitis, the most serious common adverse reaction is defined as serum aspartate aminotransferase (AST) level more that three times the upper limit of normal in the presence of symptoms or five times the upper limit of normal in absence of symptoms.
It should be noted that TB itself may involve the liver, causing abnormal liver function. Thus, not all abnormalities in liver function tests noted at baseline should be attributed to causes other than TB. Hepatic abnormalities caused by TB will improve with effective treatment. 33 Prior to treatment, serologic testing for hepatitis viruses A, B, and C should be performed especially if the patient uses alcohol. Close monitoring with repeat measurements of serum AST and bilirubin and symptom review is essential in managing a patient with elevated serum AST. 34 To monitor for hepatitis:
Conduct clinical monitoring on the first visit and repeat monthly to check for signs of hepatitis.
Educate patients about symptoms and signs of adverse reactions, and instruct patients to stop treatment should symptoms occur. Symptoms of adverse reactions include anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of hands a feed, persistent fatigue, weakness or fever lasting three or more days, abdominal tenderness (right upper quadrant), easy bruising or bleeding, and arthralgia. 35 If the patient is on directly observed therapy, perform a symptom review at each directly observed therapy visit to assess if there are any side effects or adverse reactions.
Pregnancy and Breastfeeding
Pregnancy has minimal influence on the pathogenesis of TB or the likelihood of LTBI progressing to disease. Pregnant women should be targeted for testing only if they have a specific risk factor for LTBI or for progression of LTBI to disease. Extensive use of isoniazid (INH) during pregnancy has shown that although it readily crosses the placental barrier, the drug is not teratogenic, even when given during the first four months of gestation. Pregnant women taking INH should receive pyridoxine supplementation.
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Breastfeeding is not contraindicated when the mother is being treated for LTBI. However, infants whose breastfeeding mothers are taking INH should receive supplemental pyridoxine. Note that the amount of INH provided by breast milk is inadequate for treatment of the infant. This module is entirely devoted to assessing and promoting adherence. It covers the many areas that need to be addressed, such as:
• Case management: assigning responsibility to the healthcare worker
• Communication and problem solving skills
• Education of the patient
• Using interpreters when needed
• Using incentives (rewards) and enablers (things that remove barriers to patients)
• Using DOT 
